Navigation Links
Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting

gnificant, in favor of the satraplatin arm.

PFS data as observed by the clinical site investigators were also presented today. Compared to the PFS data previously reported, these progression events were not adjudicated by the blinded independent review committee. The hazard ratio for PFS for the intent-to-treat population per investigator observation was 0.58 (95% CI: 0.50-0.67, p = 0.000000000002). Median time to progression was 16.0 weeks for the satraplatin arm versus 6.0 weeks for control. The hazard ratio for PFS for the intent-to-treat population treated with prior Taxotere(R) (docetaxel) per investigator observation was 0.52 (95% CI: 0.42-0.65, p=0.000000002), with a median time to progression of 15.3 weeks for the satraplatin arm compared to 5.6 weeks for control. These data are consistent with the PFS outcomes as adjudicated by the blinded independent review committee.

Safety findings in the SPARC trial were consistent with previous clinical studies involving satraplatin. Myelosuppression (decrease in the production of blood cells by the bone marrow) was the most common adverse reaction associated with satraplatin therapy. Twenty-one percent of patients in the satraplatin arm experienced grade 3 or 4 thrombocytopenia; 14% had grade 3 or 4 leucopenia and 21% had grade 3 or 4 neutropenia. Gastrointestinal disorders were the most frequent non-hematological adverse events (occurring in 57.9% of the patients receiving satraplatin). Eight percent of patients in the satraplatin arm experienced grade 3 or 4 gastrointestinal toxicities, including nausea (1.3%), vomiting (1.6%), diarrhea (2.1%) and constipation (2.1%). Additionally, 5% or less of patients in the satraplatin arm experienced grade 3 or 4 fatigue (1.7%), grade 3 or 4 infections (4.0%) and pulmonary/respiratory grade 3 or 4 toxicities (3.0%).

Preliminary data from Phase 2 trial evaluating satraplatin plus Taxol in non-small cell lung cancer also published in ASCO educational book


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:9/19/2014)... ORLANDO, Fla. , Sept. 19, 2014 /PRNewswire/ ... to grow, with the publication of two papers this ... Otolaryngology – Head and Neck Surgery , ... both objective and subjective measures of sleep disordered breathing, ... for the reduction in obstructive sleep apnea severity and ...
(Date:9/19/2014)... 2014  CytRx Corporation (Nasdaq: CYTR ), ... today announced that David J. Haen , Vice ... in the Biotech Industry Conference on Friday, September 26 th ... take place at the Millennium Broadway Hotel in ... live and archived webcast of the presentation will be ...
(Date:9/18/2014)... , September 19, 2014 ... ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition ... 2014-2018" report to their offering. ... involves the study of chromosomes using molecular ... of genes and chromosomes. It plays a ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... SAN RAMON, Calif., Aug. 20 HRI, a San Francisco ... leading the way in helping California healthcare employers comply with ... effect August 5th. , , California is ... from exposure to infectious airborne diseases, including the H1N1 flu. ...
... TITUSVILLE, N.J., Aug. 21 The U.S. Food and ... the New Drug Application (NDA) for carisbamate, an anti-epileptic ... , The NDA, filed in October 2008 ... (J&JPRD) on behalf of Ortho-McNeil-Janssen Pharmaceuticals, Inc. seeks approval ...
Cached Medicine Technology:San Ramon HR Firm Leads Response to New Cal/OSHA ATD Law 2FDA Issues Complete Response Letter for Carisbamate 2FDA Issues Complete Response Letter for Carisbamate 3
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
(Date:9/21/2014)... 2014 An experienced review website in ... hosting ranking list and announced that FatCow ( http://www.top10bestseohosting.com/go/FatCow.com/ ... suppliers. , There has been a boom in ... resulted in an increase in the number of web ... at very affordable prices. VPS (Virtual Private Server) is ...
(Date:9/21/2014)... C8 lawsuits move forward in the U.S. District ... 20 possible C8 lawsuits selected for bellwether trials ... & Schulte LLC. Court records show these six C8 ... filed that represent individuals who purportedly developed kidney cancer, ... being exposed to water contaminated by the C8 chemical ...
(Date:9/20/2014)... Vegas, NV (PRWEB) September 21, 2014 ... by Dr. Kenneth Pullman that is helping thousands of ... their diabetes symptoms without shots, pills, or prescriptions has ... review. , “There are currently tens of millions ... both Type 1 and Type 2 diabetes, and unfortunately, ...
(Date:9/20/2014)... Islands of Loreto, Baja, Mexico (PRWEB) September 20, 2014 ... of Loreto today announced the resort did not experience ... fully operational, with all amenities and activities available. , ... September 14, 2014, bringing intense wind, rain and powerful ... Baja Peninsula, Villa del Palmar Islands of Loreto experienced ...
Breaking Medicine News(10 mins):Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Top10BestSEOHosting.com: FatCow, GoDaddy And Bluehost Are The Best VPS Hosting Suppliers 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 2Health News:Villa del Palmar at the Islands of Loreto Fully Functioning After Hurricane 3
... following Congress, failure,to override SCHIP veto, WASHINGTON, Oct. ... Fattah:, "It,s a sad day when America,s children ... for and look after their most basic needs. It,s,a ... defend its most,vulnerable citizens., "The failure of the ...
... Must Happen Before Congressional Thanksgiving Break on State,Children,s ... "Congress cannot go home,to its Thanksgiving break ... of mind for America,s laboring families by passing ... Delgado, President and CEO of the,National Alliance for ...
... the Northern California Cancer Center, the University of Southern ... found that increased exposure to sunlight which increases ... decrease the risk of advanced breast cancer. , In ... Journal of Epidemiology, the researchers found that women with ...
... 2007 Research will be reported at TCT 2007, ... (CRF), that demonstrates that early intervention saves lives in ... pain. , Responding to media reports of recent studies ... to men, Dr. Alexandra J. Lansky, MD, Director of ...
... half of sufferers are kept awake by a variety of ... Along with typical symptoms such as acid reflux, the less ... coughing, choking, wheezing, choking, snoring, sore throat, and chest pain ... new U.S. survey. , The poll of 701 GERD patients ...
... Oct. 18 Following is a statement from ... the House,s failure to,override President Bush,s veto of ... of the Congressional Democrats and,some courageous Republicans to ... health care to children whose parents cannot,afford it. ...
Cached Medicine News:Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 2Health News:Exposure to sunlight may decrease risk of advanced breast cancer by half 3Health News:Are women at greater risk from angioplasty? 2
Wire lid retractor, may be clamped to surgical drape with suture or elastic band. Small pair....
Flexible rake retractor, 3 blunt prongs....
Bayonet dressing forceps serrated jaws...
Medpor Encophthalmos Wedge mimics the contour of the orbital floor and provides volume to restore the orbit to its normal shape and size....
Medicine Products: